What is HC Wainwright’s Estimate for SNDX FY2029 Earnings?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Research analysts at HC Wainwright decreased their FY2029 earnings per share estimates for shares of Syndax Pharmaceuticals in a report issued on Wednesday, August 5th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of $2.28 for the year, down from their previous forecast of $2.59. HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ FY2030 earnings at $3.16 EPS.

SNDX has been the subject of several other research reports. Bank of America reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday. Weiss Ratings downgraded shares of Syndax Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. UBS Group restated a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Friday, June 12th. Finally, Barclays lifted their price target on Syndax Pharmaceuticals from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, May 1st. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.36.

Syndax Pharmaceuticals Trading Up 4.4%

NASDAQ:SNDX opened at $19.92 on Thursday. The firm’s 50 day moving average is $20.41 and its 200 day moving average is $21.37. Syndax Pharmaceuticals has a 12 month low of $12.10 and a 12 month high of $25.59. The stock has a market capitalization of $1.77 billion, a PE ratio of -7.94 and a beta of 0.40. The company has a current ratio of 5.47, a quick ratio of 5.06 and a debt-to-equity ratio of 8.26.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.10). The company had revenue of $72.79 million for the quarter, compared to the consensus estimate of $79.36 million. Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 298.76%. Syndax Pharmaceuticals’s quarterly revenue was up 91.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.83) EPS.

Insider Activity

In other Syndax Pharmaceuticals news, CMO Nicholas A.J. Botwood sold 34,280 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $18.00, for a total value of $617,040.00. Following the sale, the chief marketing officer owned 60,885 shares of the company’s stock, valued at $1,095,930. This trade represents a 36.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Michael A. Metzger sold 32,375 shares of the business’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $24.24, for a total value of $784,770.00. Following the transaction, the chief executive officer directly owned 484,843 shares of the company’s stock, valued at $11,752,594.32. The trade was a 6.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 105,914 shares of company stock valued at $2,120,789. 4.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Large investors have recently modified their holdings of the company. Palumbo Wealth Management LLC bought a new stake in Syndax Pharmaceuticals during the 4th quarter valued at $1,079,000. Torray Investment Partners LLC purchased a new stake in shares of Syndax Pharmaceuticals during the fourth quarter worth about $2,055,000. Eventide Asset Management LLC increased its holdings in Syndax Pharmaceuticals by 25.3% during the 4th quarter. Eventide Asset Management LLC now owns 1,238,196 shares of the company’s stock valued at $26,014,000 after purchasing an additional 249,710 shares during the period. Orbimed Advisors LLC bought a new position in Syndax Pharmaceuticals during the 1st quarter valued at approximately $22,479,000. Finally, Voss Capital LP bought a new stake in shares of Syndax Pharmaceuticals in the 4th quarter worth approximately $2,626,000.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.